Pulmonx Corp (LUNG)
$2.38-$0.04 (-1.65%) Today
David Aaron Lehman - OfficerDavid Aaron Lehman - OfficerDavid Aaron Lehman - OfficerDavid Aaron Lehman - OfficerPulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 15 | 93,263 | $144K |
| Grant or award | 6 | 240,000 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
39 Form 4 filings on record, the earliest from Oct 21, 2024, newest first. Filing history page 2 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Dana G. Mead Jr. | Grant or award | Common Stock | 37,153 | $0.00 | - | |
| Tiffany Sullivan | Grant or award | Common Stock | 37,153 | $0.00 | - | |
| Glendon E. French III | Grant or award | Common Stock | 37,153 | $0.00 | - | |
| Daniel P. Florin | Grant or award | Common Stock | 37,153 | $0.00 | - | |
 Thomas William Burns | Grant or award | Common Stock | 37,153 | $0.00 | - | |
| David Aaron Lehman - Officer | Open-market sale | Common Stock | 410 | $6.18 | $3K | |
| David Aaron Lehman - Officer | Open-market sale | Common Stock | 722 | $6.19 | $4K | |
| David Aaron Lehman - Officer | Open-market sale | Common Stock | 2,755 | $6.19 | $17K | |
| David Aaron Lehman - Officer | Open-market sale | Common Stock | 1,610 | $6.18 | $10K | |
 Geoffrey Beran Rose - Officer | Open-market sale | Common Stock | 392 | $6.19 | $2K | |
| Geoffrey Beran Rose - Officer | Open-market sale | Common Stock | 690 | $6.18 | $4K | |
| Geoffrey Beran Rose - Officer | Open-market sale | Common Stock | 1,756 | $6.19 | $11K | |
| Geoffrey Beran Rose - Officer | Open-market sale | Common Stock | 1,538 | $6.18 | $10K | |
| Glendon E. French III | Open-market sale | Common Stock | 20,000 | $6.63 | $133K | |
| Glendon E. French III | Open-market sale | Common Stock | 20,000 | $6.52 | $130K |
This is as far as the anonymous view goes. Create a free account for all 39 LUNG filings on record.
Pulmonx Corp (LUNG) had 10 insider filings in the last 90 days, with the most recent on 2026-06-09. The full record for LUNG runs to 39 Form 4 filings, the earliest from 2024-10-21. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of LUNG were filed in the last 90 days. 1 purchase is on record for this company.
15 insider sales of LUNG were filed in the last 90 days, totaling $144K.
This page tracks LUNG Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add LUNG to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
